• NIFTY  
    11,017.00
    (-0.33%)
  • SENSEX  
    37,328.01
    ( -0.20%)
  • USDINR  
    71.16
    ( -0.07%)
  • GOLD  
    37,980.00
    ( 0.42%)
  • Hot Pursuit - Detailed News
Alembic Pharma spurts after USFDA nod for glycemic control drug
23-Jul-19   13:21 Hrs IST

The announcement was made during market hours today, 23 July 2019.

Meanwhile, the S&P BSE Sensex was up by 62.17 points or 0.16% to 38,093.75.

On the BSE, 3334 shares were traded in the counter so far compared with average daily volumes of 3658 shares in the past two weeks. The stock had hit a high of Rs 536.15 and a low of Rs 515. The stock hit a 52-week high of Rs 664 on 27 September 2018 and a 52-week low of Rs 435.1 on 21 June 2019.

Alembic Pharmaceuticals announced that it has received a tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Dapagliflozin tablets, 5 mg and 10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD) Farxiga tablets of 5 mg and 10 mg. Dapagliflozin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

According to IQVIA, Dapagliflozin tablets have an estimated market size of $1.7 billion for twelve months ending December 2018.

Alembic Pharmaceuticals' consolidated net profit rose 32.2% to Rs 124 crore on 8.6% rise in net sales to Rs 926.95 crore in Q4 March 2019 over Q4 March 2018.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company.

Powered by Capital Market - Live News

Useful Links

Back to Top
Attention Investors
Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day.............issued in the interest of investors. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account                                    "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
Investors should be cautious of unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.BSE   http://www.bseindia.com/investors/tip-off-registration.aspx?expandable  NSE   https://www.nseindia.com/int_invest/dynacontent/any_portal.htm
All payments to Stock Broker shall be received from the market intermediaries/participants strictly by account payee crossed cheques / demand drafts or by way of direct credit into the bank account through electronic fund transfer, or any other mode permitted by the Reserve Bank of India. Stock Brokers shall not accept cash from their clients either directly or by way of cash deposit to the Bank Account of Stock Broker.
Group Companies Members of : BSE, NSE, MCX, MCX.SX, CDSL, NCDEX, Broking Services, Depository Services, Portfolio Management Services, Member Area IPO Distribution, Insurance Broking
BSE Clearing No.: 911 | SEBI Regn. No.: INZ000177531 (Cash/F&O) | NSE Clearing No.: 11858 | SEBI Regn. No. INZ000177531 (Cash/F&O/CDs) | MCX-SX Clearing No.: 11400 | SEBI Regn. No.: INZ000177531 (CDs) | CDSL DP ID: 30300 | SEBI Regn. No.: IN-DPCDSL-210-2003 | MCX SEBI Reg No.: INZ000032336 | MCX: 10665 | NCDEX: 00254 | NBFC RBI Regn. No.: 13.01851
© Copyright 2018 Ajmera Associates Ltd ( ISO 9001:2015 Certified )
Designed, Developed and Powered By CMOTS Infotech ( ISO 9001:2015 Certified )
Open An Account Today !